GGT1 and metabolic dysfunction-associated steatotic liver disease: We hypothesize that this may be due to several factors: the study sample, which included one-third of mild NAFLD patients, exhibited higher GGT levels but lower SAF scores, potentially introducing selection bias; GGT levels might be affected by uncontrolled factors such as medications and lifestyle choices, which were not adequately controlled in this study; and the liver may react to early fatty degeneration and inflammation through compensatory mechanisms, leading to elevated GGT levels that could decrease as the disease progresses to more severe stages (35).